D. Shah

Personalized medicine: is it a pharmacogenetic mirage?

R. Shah, D. Shah, 2012, British journal of clinical pharmacology.

Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Stanley B. Cohen, D. Symmons, M. Dougados, 2011 .

Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer Patients

S. Dholakia, R. Shah, D. Shah, 2014, Drug Safety.

A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.

R. Shah, D. Shah, Samantha A. Roberts, 2013, British journal of clinical pharmacology.

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

R. Shah, J. Morganroth, D. Shah, 2013, Drug Safety.

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology

R. Shah, D. Shah, 2019, Drug Safety.

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

R. Shah, J. Morganroth, D. Shah, 2013, Drug Safety.

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

Joel Morganroth, R. Shah, J. Morganroth, 2013, Drug Safety.